Aurobindo Pharma (NSE:AUROPHARMA) Total Liabilities : ₹171,380 Mil (As of Mar. 2025)

View and export this data going back to 2000. Start your Free Trial

What is Aurobindo Pharma Total Liabilities?

Aurobindo Pharma's Total Liabilities for the quarter that ended in Mar. 2025 was ₹171,380 Mil.

Aurobindo Pharma's quarterly Total Liabilities declined from Sep. 2024 (₹172,094.90 Mil) to Dec. 2024 (₹0.00 Mil) but then increased from Dec. 2024 (₹0.00 Mil) to Mar. 2025 (₹171,380.40 Mil).

Aurobindo Pharma's annual Total Liabilities increased from Mar. 2023 (₹130,381.40 Mil) to Mar. 2024 (₹152,207.10 Mil) and increased from Mar. 2024 (₹152,207.10 Mil) to Mar. 2025 (₹171,380.40 Mil).

Aurobindo Pharma Total Liabilities Historical Data

The historical data trend for Aurobindo Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Total Liabilities Chart

Aurobindo Pharma Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Total Liabilities

Get a 7-Day Free Trial

119,250.00

93,476.70

130,381.40

152,207.10

171,380.40

Aurobindo Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															152,207.10	-	172,094.90	-	171,380.40

Aurobindo Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aurobindo Pharma's Total Liabilities for the fiscal year that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	146823.4	+	(18008.6	+	6548.4
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	171,380

Total Liabilities	=	Total Assets (A: Mar. 2025 )	-	Total Equity (A: Mar. 2025 )
	=	497849.7	-	326469.3
	=	171,380

Aurobindo Pharma's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	146823.4	+	(18008.6	+	6548.4
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	171,380

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	497849.7	-	326469.3
	=	171,380

Aurobindo Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurobindo Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (NSE:AUROPHARMA) » Definitions » Total Liabilities

Traded in Other Exchanges

524804:India

Address

Plot No. 1, Survey No. 83/1, Galaxy, Floors 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500032

Website

https://www.aurobindo.com

Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. It is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Its formulations target key therapeutic areas, including Central Nervous System (CNS), Antibiotics, Anti-diabetics, Cardiovascular, Anti-retroviral, Gastroenterology, Oncology, and Dermatology. The operating and reportable segments of the company are; India, the United States of America, Europe, and the Rest of the World. The company generates a majority of its revenue from its business in the United States of America.

Aurobindo Pharma Headlines

No Headlines